Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Buy” from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $34.75.

A number of analysts have recently issued reports on the stock. JMP Securities lowered their price objective on shares of Viridian Therapeutics from $36.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, March 11th. Zacks Investment Research lowered shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 16th.

In other news, insider Jonathan Violin sold 16,751 shares of Viridian Therapeutics stock in a transaction dated Tuesday, February 1st. The shares were sold at an average price of $19.55, for a total value of $327,482.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 47,660 shares of company stock valued at $912,534 over the last three months. 8.70% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dorsey Wright & Associates bought a new position in shares of Viridian Therapeutics during the 1st quarter worth approximately $46,000. Morgan Stanley bought a new position in Viridian Therapeutics during the second quarter worth $128,000. Bank of America Corp DE boosted its position in Viridian Therapeutics by 5,399.4% during the fourth quarter. Bank of America Corp DE now owns 9,514 shares of the company’s stock worth $188,000 after purchasing an additional 9,341 shares during the period. Sender Co & Partners Inc. bought a new position in shares of Viridian Therapeutics in the fourth quarter valued at about $242,000. Finally, PDT Partners LLC acquired a new stake in shares of Viridian Therapeutics during the 4th quarter worth about $249,000.

VRDN opened at $14.00 on Friday. The business’s 50-day moving average price is $18.31 and its two-hundred day moving average price is $18.81. Viridian Therapeutics has a 1 year low of $10.44 and a 1 year high of $22.00. The company has a market capitalization of $362.78 million, a price-to-earnings ratio of -1.82 and a beta of 0.99.

Viridian Therapeutics (NASDAQ:VRDNGet Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.47). The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the previous year, the firm posted ($5.31) EPS. Research analysts expect that Viridian Therapeutics will post -3.68 EPS for the current year.

About Viridian Therapeutics (Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Featured Articles

Analyst Recommendations for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with's FREE daily email newsletter.